tbuckley/cabot-search huggingface dataset:
MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007
Authors: N. Hylton, J. Blume, C. Gatsonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. Esserman, M. Schnall
Journal: Journal of Clinical Oncology (2009)

529 Background: American College of Radiology Imaging Network (ACRIN) trial 6657, the imaging component of the I-SPY trial (CALGB 150007/150012), is testing MRI for predicting response to treatment and stratifying risk-of-recurrence in patients with locally-advanced breast cancer. We report preliminary results evaluating MRI for prediction of pathologic response. Methods: Women with ≥3 cm invasive breast cancer receiving neoadjuvant chemotherapy (NACT) with anthracycline-cyclophosphamide (AC) followed by a taxane (T) were enrolled from May 2002 to March 2006. MRI was performed prior to NACT (t1), after 1 cycle AC (t2), between AC and T (t3), and following T prior to surgery (t4). MRI tumor size assessments included longest diameter (MRLD) and tumor volume (MRVol). Clinical size (clinsize) and mammographic longest diameter (MGLD) were also recorded. Linear dimension was measured by the radiologist for MGLD and MRLD; MRVol was calculated by computer using signal enhancement ratio (SER) thresholds. Change in clinical and MRI variables at t2 were compared for ability to predict pathologic complete response (pCR). Results: 237 patients were enrolled at 9 institutions. 216 patients with complete imaging were analyzed. Of tumor size measurements at t4, MRVol showed the strongest correlation with pathsize among clinsize (r = 0.44), MGLD (ns), MRLD (r = 0.28) and MRVol (r = 0.61). Early change in MRVol measured at t2 was the only variable predictive of pCR among clinsize (p = 0.14, 0.15), MRLD (p = 0.40, 0.07), MRVol (p = 0.02, 0.01) and peak SER (p = 0.53, 0.72) in univariate and multivariate logistic regression, respectively. Conclusions: Tumor response measured volumetrically by MRI is a stronger and earlier predictor of pathologic response after NACT than clinical exam or tumor diameter. This work is funded by NIH/ACRIN U01 CA79778; CALGB CA31946, CA33601; NCI SPORE CA58207. [Table: see text]
Abnormal melatonin response to 5-methoxypsoralen in dementia
Authors: E Souêtre, E Salvati, B Krebs, J L Belugou, G Darcourt
Journal: American Journal of Psychiatry (1989)

The authors investigated the melatonin response to 5-methoxypsoralen in 39 healthy adult and elderly subjects and in 13 demented, 13 depressed, and 13 schizophrenic inpatients. Subjects' plasma melatonin levels were evaluated before they took single, oral 40-mg doses of 5-methoxypsoralen and 3 hours afterward. The preliminary results indicate that the melatonin response of the pineal gland to 5-methoxypsoralen is reduced in demented patients compared to that in healthy elderly subjects. Depressed and schizophrenic patients had a normal melatonin response to the drug. This finding suggests that the pineal gland may be functionally impaired in dementia but not in depression.
Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer
Authors: S. Vukelja, D. Richards, L. T. Campos, C. Bedell, C. Hagenstad, W. Hyman, J. Letzer, L. Gardner, P. Sportelli, J. Nemunaitis
Journal: Journal of Clinical Oncology (2009)

4081 Background: Perifosine (Peri), a synthetic alkylphospholipid, inhibits or modifies a number of different signal transduction pathways (AKT, MAPK and JNK). Peri as a single agent or in combination with other cytotoxic agents, has shown clinical benefit with a manageable safety profile. In a phase I solid tumor trial, Peri was safely combined with capecitabine (Cap) and demonstrated interesting activity in patients (pts) with metastatic colorectal cancer (mCRC), with one patient progression-free for 49 weeks (wks). To assess the true effect of Peri, a phase II was initiated as an exploratory randomized double-blind, placebo controlled study where mCRC pts received Cap in combination with Peri or placebo. Methods: Pts with 2 nd or 3 rd line mCRC, not previously treated with single agent Cap. ECOG PS 0–1, normal organ/marrow function required. Dose for Cap was 825 mg/m 2 BID d 1–14 q 3 weeks. Dose for Peri or placebo was 50 mg qd. Primary outcome analyses included median time to progression (TTP) and response rate (CR+PR). Results: 37 pts have been randomized. Median age 68 (range 32–83) and 57% were male. Median prior Rx was 2 (range 1 - 5). For the analyses, 25 pts were unblinded (12 too early) with 22/25 pts evaluable for response (2 pts off for toxicity at d 14, 46 and 1 patient off at d 4 for other disease; all 3 pts were on Cap + placebo). Results in table below. The log-rank p-value comparing active to placebo for TTP is 0.01. As of 12/08, all unblinded pts are off treatment and 11/12 that were too early remain on treatment with enrollment ongoing. Most frequent (&gt;5%) grade 3 /4 adverse events for Cap + Peri was hand/foot syndrome (16%) and anemia (8%); for Cap + placebo was fatigue (8%). Conclusions: Perifosine in combination with capecitabine was well tolerated, clinically active and more than doubled median TTP over capecitabine alone in pts with advanced, metastatic CRC. [Table: see text] [Table: see text]
Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer.
Authors: J. H. Borovicka, M. F. Mulcahy, C. Calahan, D. P. West, M. E. Lacouture
Journal: Journal of Clinical Oncology (2010)

3569 Background: Dermatologic toxicities including rash, xerosis, pruritus, paronychia, alopecia, mucositis and infections occur in up to 100% of colorectal cancer (CRC) patients treated with EGFRIs. These toxicities negatively affect quality of life but the associated financial impact has not been previously reported. This study evaluates the costs associated with management of cutaneous toxicities attributed to cetuximab in patients with CRC, who were referred to a dermatology-based program for the management of dTs in oncology, the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and Kinases) clinic. Methods: Medical records for a subset of 29 patients with CRC treated with cetuximab were indentified. Patient costs for dT related clinic visits, laboratory studies, diagnostic procedures, medications and supplies were assessed. Results: All patients (100%) presented with rash in addition to xerosis (72%), pruritus (38%), paronychia (34%) and alopecia (14%). A total of 29 patients had 99 clinic visits related to toxicity management. Total cost was $82,432 (mean = $2,842/patient). Mean number of visits per patient was 3.4 (range 1-11) at a mean cost of $824 per visit (range $131-8,451). The patient cost for prescription medications (topical and oral) was $44,114 (mean = $1,521/patient, range $1-6,611). A total of 288 prescriptions were written (mean = 9.9/patient, range 2-37). Total cost for laboratory testing was $5,439 (mean = $188/patient, range $0-720). The total cost for diagnostic and therapeutic procedures such as skin biopsy and destruction of lesions was $6,914 (mean = $238/patient, range $0-1,046). The total billable amount for clinic visits was $25,117 (mean = $866/patient, range $469-10,909). Conclusions: The economic burden of dT associated with cetuximab contributes markedly to the overall financial burden of CRC care. Interventions that prophylactically mitigate the cetuximab dT are critical for the minimization of management-related costs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, ImClone Systems, Onyx Amgen, Bayer, Bristol-Myers Squibb, ImClone Systems, Onyx Hana Biosciences
Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc
Authors: E. Calvo, V. Boni, R.S. Heist, U. Matulonis, P.A. Janne, O. Hamid, E. Holgado, J.M. Ordoñez, J. Nunez, M. Ugrenovic, W. Lin, B. O'keeffe, M.R. Lackner, J. Spoerke, J. Ware, M. Pinder-Schenck
Journal: Annals of Oncology (2014)
Recent Update to the US Cholesterol Treatment Guidelines
Authors: Matthew Nayor, Ramachandran S. Vasan
Journal: Circulation (2016)

The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline advocated several changes from the previous Adult Treatment Panel III guidelines. Assuming full implementation, the 2013 ACC/AHA guideline would identify ≈13 million Americans as newly eligible for consideration of statin therapy. Three features of the 2013 ACC/AHA guideline primarily responsible for these differences are the specific risk assessment tool endorsed, the risk threshold considered sufficient to warrant primary prevention statin therapy, and the decision not to include cholesterol treatment targets. There is no consensus among international guidelines on the optimal approach to these 3 components. The 2013 ACC/AHA guideline recommends assessing absolute risk with the Pooled Cohort equations, which were developed to improve on previous risk assessment models by including stroke as an outcome and by broadening racial and geographic diversity. Each of the leading international guidelines recommends a different equation for absolute risk assessment. The 2013 ACC/AHA guideline advises consideration of statin therapy for an estimated 10-year risk of atherosclerotic vascular disease of ≥7.5%, which is lower than the thresholds recommended by other leading international guidelines. Lastly, the 2013 ACC/AHA guideline does not endorse a treat-to-target strategy but instead specifies the appropriate intensity of statin for each risk category. This approach is shared by the National Institute for Health and Care Excellence guidelines but differs from other international guidelines. In this review, we summarize the 2013 ACC/AHA cholesterol guideline recommendations and compare them with recommendations from Adult Treatment Panel III and other leading international guidelines.
Cleaning House—Environmental Contamination in the Home
Authors: Mitchell H. Katz
Journal: JAMA Internal Medicine (2016)

Justin Knox, MPH; Sean B. Sullivan, MPH; Julia Urena, BA; Maureen Miller, PhD; Peter Vavagiakis, MS; Qiuhu Shi, PhD; Anne-Catrin Uhlemann, MD, PhD; Franklin D. Lowy, MD
Manic syndrome in AIDS
Authors: K Kieburtz, A E Zettelmaier, L Ketonen, M Tuite, E D Caine
Journal: American Journal of Psychiatry (1991)

A manic syndrome in eight patients with AIDS is described. On the basis of clinical, neuropsychological, laboratory, magnetic resonance imaging, and epidemiological evidence, the authors suggest that the manic syndrome was secondary to HIV infection. The patients also developed concomitant cognitive impairment.
IMPS-22FGL2 AS A MULTI-MODALITY REGULATOR OF TUMOR-MEDIATED IMMUNE SUPPRESSION
Authors: Jun Yan, Ling-Yuan Kong, Jiemiao Hu, Konrad Gabrusiewicz, Denada Dibra, Xueqing Xia, Amy Heimberger, Shulin Li
Journal: Neuro-Oncology (2015)
Case report: Denosumab was useful for the unresectable giant cell tumor of the skull
Authors: Takeshi Shiraishi, Yoshinori Kajiwara, Ikuo Takahashi, Yuko Tokuno, Ikuko Yamaguchi, Hiroki Hashimoto, Michiyasu Murakami, Tomoaki Fjisaki, Motohiro Fujii, Takashi Nishizaki
Journal: Annals of Oncology (2015)
Gender, type of treatment, dysfunctional attitudes, social support, life events, and depressive symptoms over naturalistic follow-up
Authors: C Zlotnick, M T Shea, P A Pilkonis, I Elkin, C Ryan
Journal: American Journal of Psychiatry (1996)

The present study investigated gender differences in depressive symptoms during a naturalistic follow-up for outpatients with major depressive disorder in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Specifically, the study investigated whether gender interacted with type of treatment received, dysfunctional attitudes, life events, or social support to predict severity of depressive symptoms. In addition, aspects of these psychosocial factors (need for approval, interpersonal life events, and close friendships), hypothesized to be more salient for women, were examined to determine if they had a differential impact on level of depressive symptoms in men and women. Assessments conducted 6, 12, and 18 months after treatment included measures of depressive symptoms, dysfunctional attitudes, current life events, and social support. Data were available for 188 subjects (134 women and 54 men). Regression analyses were conducted to examine whether gender as a main effect, or interacting with dysfunctional attitudes, life events, social support, or subtypes of these variables, predicted cross-sectional or longitudinal measures of depressive symptoms during follow-up. A consistent finding of the study was that over the 18 months of this naturalistic follow-up, there were no main effects for gender or any significant interactions involving gender and any of the variables of interest. The study demonstrated that life events and social support were related to severity of depressive symptoms for both genders. Despite differential prevalence rates of major depression for men and women, findings do not support a different process in outcome of illness for men and women.
Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer
Authors: Yan-qi Huang, Chang-hong Liang, Lan He, Jie Tian, Cui-shan Liang, Xin Chen, Ze-lan Ma, Zai-yi Liu
Journal: Journal of Clinical Oncology (2016)

To develop and validate a radiomics nomogram for preoperative prediction of lymph node (LN) metastasis in patients with colorectal cancer (CRC).The prediction model was developed in a primary cohort that consisted of 326 patients with clinicopathologically confirmed CRC, and data was gathered from January 2007 to April 2010. Radiomic features were extracted from portal venous-phase computed tomography (CT) of CRC. Lasso regression model was used for data dimension reduction, feature selection, and radiomics signature building. Multivariable logistic regression analysis was used to develop the predicting model, we incorporated the radiomics signature, CT-reported LN status, and independent clinicopathologic risk factors, and this was presented with a radiomics nomogram. The performance of the nomogram was assessed with respect to its calibration, discrimination, and clinical usefulness. Internal validation was assessed. An independent validation cohort contained 200 consecutive patients from May 2010 to December 2011.The radiomics signature, which consisted of 24 selected features, was significantly associated with LN status (P < .001 for both primary and validation cohorts). Predictors contained in the individualized prediction nomogram included the radiomics signature, CT-reported LN status, and carcinoembryonic antigen level. Addition of histologic grade to the nomogram failed to show incremental prognostic value. The model showed good discrimination, with a C-index of 0.736 (C-index, 0.759 and 0.766 through internal validation), and good calibration. Application of the nomogram in the validation cohort still gave good discrimination (C-index, 0.778 [95% CI, 0.769 to 0.787]) and good calibration. Decision curve analysis demonstrated that the radiomics nomogram was clinically useful.This study presents a radiomics nomogram that incorporates the radiomics signature, CT-reported LN status, and clinical risk factors, which can be conveniently used to facilitate the preoperative individualized prediction of LN metastasis in patients with CRC.
Abstract 3119: Vascular Remodelling of the IMA-Graft Early and Late after Bypass Surgery
Authors: Beat H Walpoth, Markus Schmid, Anna Schwab, Mustafa Cikirikcioglu, F. Eckstein, Thierry Carrel, Otto M Hess
Journal: Circulation (2006)

Objective: Flow mismatch between the supplying vessel and the perfusion region has been observed in patients with internal mammary artery (IMA) grafts. However, arterial graft remodelling has been postulated after CABG. The purpose of this study was to assess flow changes of arterial (IMA) and venous bypass grafts (SVG) after CABG. Methods: 42 patients undergoing elective bypass surgery were included in the present analysis. Patients were studied intra-, early (4 months; n=12) and late (12 months; n=5) post-operatively. Coronary flow was measured intra-operatively with the transit time Doppler technique (CardioMed, Norway) in the IMA and one SVG. Post-operatively patients were re-catheterized 4 and 12 months after surgery and coronary bypass flow as well as flow reserve (CFR) was measured with the Doppler flow-wire technique in the IMA and SVG. Quantitative angiography was used to determine vessel size for calculation of absolute coronary flow. Wilcoxon Signed Ranks Test was used for paired observations a...
Addressing Infection Prevention and Control in the First U.S. Community Hospital to Care for Patients With Ebola Virus Disease: Context for National Recommendations and Future Strategies
Authors: Kristin J. Cummings, Mary J. Choi, Eric J. Esswein, Marie A. de Perio, Joshua M. Harney, Wendy M. Chung, David L. Lakey, Allison M. Liddell, Pierre E. Rollin
Journal: Annals of Internal Medicine (2016)

Health care personnel (HCP) caring for patients with Ebola virus disease (EVD) are at increased risk for infection with the virus. In 2014, a Texas hospital became the first U.S. community hospital to care for a patient with EVD; 2 nurses were infected while providing care. This article describes infection control measures developed to strengthen the hospital's capacity to safely diagnose and treat patients with EVD. After admission of the first patient with EVD, a multidisciplinary team from the Centers for Disease Control and Prevention (CDC) joined the hospital's infection preventionists to implement a system of occupational safety and health controls for direct patient care, handling of clinical specimens, and managing regulated medical waste. Existing engineering and administrative controls were strengthened. The personal protective equipment (PPE) ensemble was standardized, HCP were trained on donning and doffing PPE, and a system of trained observers supervising PPE donning and doffing was implemented. Caring for patients with EVD placed substantial demands on a community hospital. The experiences of the authors and others informed national policies for the care of patients with EVD and protection of HCP, including new guidance for PPE, a rapid system for deploying CDC staff to assist hospitals ("Ebola Response Team"), and a framework for a tiered approach to hospital preparedness. The designation of regional Ebola treatment centers and the establishment of the National Ebola Training and Education Center address the need for HCP to be prepared to safely care for patients with EVD and other high-consequence emerging infectious diseases.
Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab
Authors: Ken Chang, Biqi Zhang, Xiaotao Guo, Min Zong, Rifaquat Rahman, David Sanchez, Nicolette Winder, David A Reardon, Binsheng Zhao, Patrick Y. Wen, Raymond Y Huang
Journal: Neuro-Oncology (2016)

Abstract Background Bevacizumab is a humanized antibody against vascular endothelial growth factor approved for treatment of recurrent glioblastoma. There is a need to discover imaging biomarkers that can aid in the selection of patients who will likely derive the most survival benefit from bevacizumab. Methods The aim of the study was to examine if pre- and posttherapy multimodal MRI features could predict progression-free survival and overall survival (OS) for patients with recurrent glioblastoma treated with bevacizumab. The patient population included 84 patients in a training cohort and 42 patients in a testing cohort, separated based on pretherapy imaging date. Tumor volumes of interest were segmented from contrast-enhanced T1-weighted and fluid attenuated inversion recovery images and were used to derive volumetric, shape, texture, parametric, and histogram features. A total of 2293 pretherapy and 9811 posttherapy features were used to generate the model. Results Using standard radiographic assessment criteria, the hazard ratio for predicting OS was 3.38 (P &lt; .001). The hazard ratios for pre- and posttherapy features predicting OS were 5.10 (P &lt; .001) and 3.64 (P &lt; .005) for the training and testing cohorts, respectively. Conclusion With the use of machine learning techniques to analyze imaging features derived from pre- and posttherapy multimodal MRI, we were able to develop a predictive model for patient OS that could potentially assist clinical decision making.
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: Enzamet (Anzup 1304)
Authors: I.D. Davis, M.R. Stockler, A. Martin, A. Long, S. Yip, X. Coskinas, C. Sweeney
Journal: Annals of Oncology (2014)
Early child-rearing practices in families with a manic-depressive parent
Authors: Y B Davenport, C Zahn-Waxler, M L Adland, A Mayfield
Journal: American Journal of Psychiatry (1984)

Nurturing attitudes and behaviors among seven married couples, each of which contained one partner who had manic-depressive illness, and their young children were compared with those of normal control families. Mothers from index families, in contrast to control mothers, were less attentive to their children's health needs, emphasized performance in some achievement-related areas, were more overprotective, and reported more negative affect toward the child. They also were more disorganized, less active with their children, and more unhappy, tense, and ineffective. Index parents secured lower scores in the areas of family interaction and social adjustment, and they experienced situational problems of considerable severity, including clinical depression in the well parent.